Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07325136CT.gov A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT04702880CT.gov A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04610658CT.gov Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | — | Terminated | — | — | — |
NCT04173325CT.gov Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04165330CT.gov Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03958045CT.gov Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | — | Completed | — | — | — |
NCT03850067CT.gov A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
Show 10 more trialsShow fewer
NCT03670056CT.gov Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03575793CT.gov A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03583086CT.gov Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | — | Completed | — | — | — |
NCT03406715CT.gov Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | — | Terminated | — | — | — |
NCT03223155CT.gov Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03083691CT.gov BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | — | Completed | — | — | — |
NCT03026166CT.gov A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03043599CT.gov Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02046733CT.gov Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | — | Completed | — | — | — |
NCT02247349CT.gov BMS-986012 in Relapsed/Refractory SCLC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Bristol-Myers Squibb | P2 | B · 62 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →